Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0V0NL
|
|||
| Former ID |
DNC000203
|
|||
| Drug Name |
Aminoguanidine
|
|||
| Synonyms |
aminoguanidine; Pimagedine; Hydrazinecarboximidamide; Guanyl hydrazine; Monoaminoguanidine; 2-aminoguanidine; 79-17-4; Imino semicarbazide; Aminate base; 2-azanylguanidine; Pimagedine [INN]; GUANIDINE, AMINO-; 1-aminoguanidine; UNII-SCQ4EZQ113; Hydrazinecarboximidamide(9CI); CCRIS 3511; EINECS 201-183-1; Aminoguanidine, Hemisulfate; SCQ4EZQ113; CHEMBL225304; CHEBI:40618; HAMNKKUPIHEESI-UHFFFAOYSA-N; guanylhydrazine; GER-11; AGU; amino guanidine; 1-amino-guanidine; Aminoguanidine (AG); Tocris-0787; Carbonohydrazonic diamide; INCB3284
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Diabetic retinopathy [ICD-11: 9B71.0; ICD-10: H36.0; ICD-9: 250.5] | Phase 1 | [1] | |
| Insulin-resistant disorder [ICD-11: 5A44; ICD-10: E10-E14] | Discontinued in Phase 2 | [2] | ||
| Rheumatoid arthritis [ICD-11: FA20] | Discontinued in Phase 2 | [2] | ||
| Structure |
 |
Download2D MOL |
||
| Formula |
CH6N4
|
|||
| Canonical SMILES |
C(=NN)(N)N
|
|||
| InChI |
1S/CH6N4/c2-1(3)5-4/h4H2,(H4,2,3,5)
|
|||
| InChIKey |
HAMNKKUPIHEESI-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 79-17-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
613675, 4656528, 7885775, 8151457, 10536095, 11110767, 11110768, 11113705, 12014685, 15170355, 16447240, 26717094, 26758204, 29221325, 30387223, 37457865, 38636745, 42873743, 46506441, 47216879, 47736599, 48110553, 49974251, 50104571, 50104572, 50807510, 53788780, 57321170, 87322642, 88824429, 90341334, 90341800, 103513944, 103825641, 104084871, 104299739, 117516744, 124749450, 124879244, 124879245, 124879246, 125334778, 126546077, 127649709, 128032796, 129532113, 129852663, 134339310, 134339703, 134340037
|
|||
| ChEBI ID |
CHEBI:40618
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02099981) Restoration of Retinal Vascular Responses in Type 1 Diabetic Patients in University of Minnesota - Clinical and Translational Science Institute. | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018258) | |||
| REF 3 | Incyte Announces Second Quarter 2005 Financial Results; Reports Positive Phase IIb Results for Reverset in Treatment-Experienced HIV Patients. Incyte Corporation. 2005. | |||
| REF 4 | Inhibitory effects of aminoguanidine on thyroid follicular carcinoma development in inflamed capsular regions of rats treated with sulfadimethoxine... Cancer Sci. 2009 Oct;100(10):1794-800. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.